Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia. by Watson, Alexander S et al.
OPEN
ARTICLE
Autophagy limits proliferation and glycolytic metabolism in
acute myeloid leukemia
AS Watson1,2, T Riffelmacher2, A Stranks2, O Williams3, J De Boer3, K Cain4, M MacFarlane4, J McGouran5, B Kessler5, S Khandwala2,
O Chowdhury6, D Puleston2, K Phadwal1, M Mortensen2, D Ferguson7, E Soilleux7, P Woll6, SEW Jacobsen6 and AK Simon1,2
Decreased autophagy contributes to malignancies; however, it is unclear how autophagy has an impact on tumor growth. Acute
myeloid leukemia (AML) is an ideal model to address this as (i) patient samples are easily accessible, (ii) the hematopoietic stem and
progenitor cells (HSPC) where transformation occurs is well characterized and (iii) loss of the key autophagy gene Atg7 in
HSPCs leads to a lethal pre-leukemic phenotype in mice. Here we demonstrate that loss of Atg5 results in an identical HSPC
phenotype as loss of Atg7, confirming a general role for autophagy in HSPC regulation. Compared with more committed/mature
hematopoietic cells, healthy human and mouse HSPCs displayed enhanced basal autophagic flux, limiting mitochondrial damage
and reactive oxygen species in this long-lived population. Taken together, with our previous findings these data are compatible
with autophagy-limiting leukemic transformation. In line with this, autophagy gene losses are found within chromosomal regions
that are commonly deleted in human AML. Moreover, human AML blasts showed reduced expression of autophagy genes and
displayed decreased autophagic flux with accumulation of unhealthy mitochondria, indicating that deficient autophagy may be
beneficial to human AML. Crucially, heterozygous loss of autophagy in an MLL–ENL model of AML led to increased proliferation
in vitro, a glycolytic shift and more aggressive leukemias in vivo. With autophagy gene losses also identified in multiple other
malignancies, these findings point to low autophagy, providing a general advantage for tumor growth.
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INTRODUCTION
Autophagy is a catabolic delivery pathway for excess or damaged
cytoplasmic constituents to the lysosomes where macromolecules
are broken down and their components freed for anabolic
activities.1
Autophagy maintains mitochondrial health and metabolic
pathways, being induced following metabolic stress, controlled
by mTOR complex 1 (mTORC1). Under favorable conditions,
activated mTORC1 signals for cell growth, promoting translation,
cell cycle progression and glycolysis2 while inhibiting autophagy.
To maximize cell mass during proliferation, suppression of self-
catabolism may be vital for growth activities. Indeed, induction of
autophagy prolongs cell survival at the cost of cell size and
growth.3,4
Activation of the Akt/mTOR pathway is a common feature of
cancers, including leukemias5 and is required for proliferation in
AML models.6 Knockout of autophagy genes in mice is associated
with hyperproliferation in some tissues7,8 and eventual tumor
development.9 Our previous studies indicated that mice without
the autophagy gene Atg7 in the hematopoietic system develop
pre-leukemic myeloproliferation.10 However, it remained unclear
how Atg7 promotes cell proliferation and whether this was an
Atg7-specific function.11 Despite oncogenic effects in these
models, the role of autophagy in cancer is controversial, with
both tumor-promoting and -inhibiting roles in leukemia
suggested.12,13
It is well accepted that transformation events leading to AML
may occur at the stem or progenitor cell stage. Hematopoietic
stem cells (HSCs) strike a fine balance between quiescence,
self-renewal and differentiation. When this balance is perturbed,
the consequences may include biased differentiation and/or
hematopoietic malignancies. In steady-state hematopoiesis, the
majority of HSCs are quiescent.14 Quiescent cells are particularly
hardy, able to survive long periods of metabolic stress. HSCs
downregulate protein synthesis and activate pathways that
sustain them during periods of non-division.15 Autophagy may
be required for maintenance of the long-lived HSC, as their slow
turnover prevents the dilution of damaged macromolecules to
daughter cells, similar to a postmitotic neuron or cardiomyocyte.16
Moreover, autophagy controls mitochondrial quality.
In this study, we find autophagy levels highest in the
most immature human and mouse hematopoietic stem and
progenitor cells (HSPCs). Monoallelic loss of a key autophagy
gene in a mouse AML model was sufficient to increase
proliferation under metabolic stress in vitro, which was dependent
on glycolytic metabolism, and led to leukemic progression in vivo.
Combined with our findings of decreased autophagy in human
AML patient blasts, these results suggest that dysregulated
1Translational Immunology Lab, BRC- NIHR, John Radcliffe Hospital, Experimental Medicine, Nuffield Department of Medicine, Oxford OX3 9DU, UK; 2MRC Human Immunology
Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK; 3Molecular Haematology and Cancer Biology Unit, UCL Institute of Child Health,
University College London, London WC1N 1EH, UK; 4MRC Toxicology Unit, Hodgkin Building, University of Leicester, PO Box 138, Lancaster Road, Leicester LE1 9HN, UK; 5Target
Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK; 6Haematopoietic Stem Cell Biology, MRC Molecular Haematology
Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK and 7Nuffield Department of Clinical and Laboratory Sciences, John Radcliffe
Hospital, Oxford OX3 9DU, UK.
Correspondence: AK Simon (katja.simon@ndm.ox.ac.uk)
Received 3 June 2015; accepted 5 June 2015; Edited by G Melino
Citation: Cell Death Discovery (2015) 1, 15008; doi:10.1038/cddiscovery.2015.8
© 2015 Cell Death Differentiation Association All rights reserved 2058-7716/15
www.nature.com/cddiscovery
autophagy function may facilitate aberrant proliferation during
AML development.
RESULTS
Human and mouse HSPCs have high basal levels of autophagy
We measured autophagic flux in mouse HSCs using three
techniques (a) CytoID, an autophagosome- and autolysosome-
pH-specific dye that can be directly detected by fluorescence
intensity using conventional flow cytometry, (b) number of
LC3-GFP puncta from transgenic mice by imaging flow cytometry
and (c) number of endogenous LC3 puncta by imaging flow
cytometry. For the latter two techniques imaging rather than
intensity measurement is required to detect LC3 fluorescence, as
upon autophagy induction LC3 relocalizes to the autophagosomal
membranes from the cytoplasm.17 CytoID showed highest basal
levels of autophagy in HSCs (Figures 1a and b). As Warr et al.18
demonstrated that mouse HSCs robustly induce autophagy after
ex vivo cytokine withdrawal using LC3-based techniques, but
failed to detect increased basal levels in murine HSCs, we next
measured autophagic flux in bone marrow (BM) from GFP-LC3
mice ex vivo by imaging flow cytometry to quantify LC3-GFP
puncta. This revealed significantly higher GFP-LC3 puncta levels in
the Lin−Sca1+cKit+ (LSK) multipotent progenitor population, which
are enriched for HSCs, relative to both the Lin−Sca1−cKit+ (LK)
oligopotent progenitors and mature hematopoietic lineages
(Figures 1c and d). Treatment with lysosomal inhibitors was
performed to confirm the positive autophagic flux.19 We finally
confirmed this result by quantifying endogenous LC3 puncta in
wild-type (WT) C57BL/6 mice (Supplementary Figure S1A).
We next measured the autophagic flux in enriched
human HSPCs using the imaging flow cytometry technique
(Supplementary Figure S1B and C). We found that CD34+ HSPCs
showed relatively higher basal autophagy levels than more
mature CD34− BM cells. Increased autophagic flux was confirmed
by lysosomal inhibition (Figure 1e). The CD34+ HSPCs also showed
improved mitochondrial health as measured by nonyl-acridine
orange and reduced levels of mitochondrial reactive oxygen
species (ROS) compared with the mature CD34− cells (Figure 1f),
maybe as a consequence of enhanced mitochondrial quality
control by mitophagy. These findings were corroborated by
RNAseq analysis of autophagy-related genes in human HSCs
and granulocyte–macrophage progenitors (GMPs). A significant
increase in expression was found for FOXO3, confirming data by
Warr et al.18 in mice and for the two Atg8 homologs GABARAPL2
and GABARAP (Figure 1g). These were the only autophagy-related
genes found to be differentially expressed between HSCs and
progenitors.
Overall, these results show that basal autophagy levels correlate
with immaturity in human and murine hematopoietic cells
compatible with an important role of autophagy in HSC function.
Autophagy levels are decreased in primary human AML blasts,
both transcriptionally and functionally
AML is characterized by usually heterozygous clonal chromosomal
abnormalities.20 Our in silico analysis found multiple key
autophagy genes21 within chromosomal regions commonly
heterozygously deleted in AML22–24 (Table 1), in particular within
regions often lost in complex karyotype AML. It is important to
note that these chromosomal regions encompass many genes,
and autophagy gene locations were often within regions more
variably lost in patients.25 However, the presence of autophagy
genes in the deleted regions was more frequent than expected by
chance (P= 0.039, Fisher’s exact test). These deletions were
accompanied by decreased mRNA expression of multiple autop-
hagy genes, in particular Atg12,24 a gene previously identified
along with lysosomal gene LAMP1 as downregulated in therapy-
related MDS cases at the time of AML transformation.26
We next sought to examine the status of the autophagy
pathway in human AML. Using AML BM samples, we sorted the
populations identified by the dominant expanded blast markers
in each patient (CD34, CD33, CD13 or combination, see
Supplementary Figure S1D) and examined the expression of the
key autophagy genes using the Fluidigm dynamic array. We found
decreased expression of autophagy genes in the dominant AML
blast cell population of the majority of donors tested when
compared with the blast marker-negative population (Figure 2a).
Human Atg8 homologs, including GAPARAPL1, GABARAPL2
(GATE-16) and MAP1LC3B, were particularly affected. There was
no clear correlation between expression levels and available
genetic/prognostic information.
To determine whether autophagy was functionally affected in
human AML, we quantified autophagy in AML blasts using
imaging flow cytometry as previously described19 and shown in
Supplementary Figure S1B. This being the only technique
applicable for such low number of cells, as both LC3 western
blot and electron microscopy require cell sorting. We found that
the expanded AML blast population had significantly lower
autophagy flux than the remaining, blast marker-negative BM
cells (Figure 2b). We also found that autophagy levels in blast
marker+ AML cells decreased compared with total CD34+ HSPCs
from healthy donors (Supplementary Figure S1D). As expected,
chloroquine abolished the colocalization of LC3 and lysosomal
marker in both populations, as it inhibits lysosomal fusion.
To further confirm the low autophagy phenotype, we examined
levels of p62, a molecule that targets cargo for autophagic
degradation, in AML BM trephine samples by immunohistochem-
istry. p62 is degraded with its cargo, thus accumulating when
autophagy is decreased.27 We found widespread positive p62
staining in seven/eight AML BM samples, compared with zero/four
healthy controls (Figure 2c), although we cannot exclude that
increased transcription of p62 contributed to this.28 It is widely
documented that autophagy controls ROS and mitochondrial
health in hematopoietic cells.29,30 Accordingly, AML blasts showed
decreased mitochondrial health and increased oxidative stress
(Figure 2d).
Identical phenotypes for Atg5 and Atg7 deficiency in HSCs
in vivo
We have previously described the HSC, myeloproliferative and
pre-leukemic phenotype of mice deficient for the essential
autophagy gene Atg7 (VavAtg7−/−).30 However, it was unclear
whether this was because of Atg7’s role in autophagy.
We therefore knocked out Atg5, another key autophagy
gene in mouse hematopoietic cells, using the Vav-Cre
promoter (VavAtg5−/−). As observed in VavAtg7−/− mice,30 all
VavAtg5−/− mice developed weight loss, lethargy along with
lymphopenia (Supplementary Figure S2A and B) and progressive
anemia (Supplementary Figure S2C and D) by 7–9 weeks
of age. Atg5−/− erythrocytes also had increased mitochondrial
content and ROS (Supplementary Figure S2E and F). The LSK
population was increased at 6 weeks in VavAtg5−/− mice and
were lost at 9 weeks (Supplementary Figure S2G), and mice
died soon after (not shown). Also similar to the Atg7 model,
monocytes/macrophages (CD11b+F4/80+, not shown) and
neutrophils (CD11b+ Gr1+; Supplementary FigureS3A and C)
accumulated in VavAtg5−/− mice in both spleen and peripheral
blood. Histopathological assessment of BM cytospins confirmed
the relative increase in neutrophils in blood and spleen
(Supplementary Figure S3A and B) and in particular of immature
myeloid cells in blood (Supplementary Figure S3D).10 Moreover,
myeloid infiltrates were observed in hematopoietic and
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Figure 1. The autophagic flux is high in human and murine HSPCs. (a) Representative histograms of CytoID staining of indicated mouse bone
marrow populations and indicated treatment, quantified as GFMI in (b) n= 2, t-test. Rapamycin serves as control inducing autophagy.
(c) Representative images and (d) quantification of ex vivo LC3-GFP puncta in LSK or LK HSPCs, CD11b+Gr1− (neutrophil) or B220+ (B cell) BM
populations from transgenic GFP-LC3 mice (‘+ I’ indicates 2 h E64D/PepA lysosomal inhibitor treatment), using Image Stream assessment of %
cells with four or more bright puncta (n= 4). (e) Frequency of CD34+ and CD34− human BM mononuclear cells in LysoID/LC3 double-positive
population with high LC3/LysoID BDS (Bright Detail Similarity; 20 000 cells analyzed per sample, n= 6 healthy donors, Wilcoxon test *Po0.05
comparing populations within donors). (f) Geometric mean fluorescent intensity (GMFI) of nonyl-acridine orange (NaO, mitochondrial health)
and (c) mitochondrial ROS (MitoSOX) staining in CD34+ and CD34− human BM cells. (g) Gene expression (RNAseq analysis) of human HSC,
GMP and MEP, n= 3 healthy donors. All bar graph values are mean values± S.E.M.; P-values are obtained with Mann–Whitney test (*Po0.05,
**Po0.01, ***Po0.001), unless otherwise stated.
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non-hematopoietic tissues (Supplementary Figure S3E), confirming
severe myeloproliferation in the absence of Atg5.
Heterozygous loss of Atg5 in AML cells promotes proliferation
in vitro and in vivo
As our previous studies suggested that accumulated pre-leukemic
Atg7-deficient cells did not harbor typical AML deletions or
translocations and were not transplantable,30 we next asked
whether autophagy has an impact on tumor growth in a mouse
leukemia model with an existing translocation. We chose the
translocation MLL–ENL as this fusion develops into an aggressive,
fully penetrant AML in vivo, demonstrating that the engineered
translocation can successfully model AML.31 Because deletion of
autophagy genes is detrimental to untransformed hematopoietic
precursors,30 we introduced the MLL–ENL fusion gene into non-
excised Atg5wt/wt, Atg5fl/wt and Atg5fl/fl hematopoietic progenitor
cells, followed by retroviral transduction with Cre to obtain Atg5
WT, HET and KO lines, respectively (depicted in Figure 3a).32,33
Genotypes of the lines were confirmed using PCR and immature
myeloid phenotype via CD11b, Gr1 and cKit expression (not
shown). Expression of the Atg5 protein in complex with Atg12 was
fully lost in KO lines and partially lost in the Atg5 HET line
(Figure 3b). We next assayed autophagy levels by LC3-II western
blot (Figure 3c) and staining with CytoID for autophagosomes and
autolysosomes (Figure 3d). Both techniques confirmed an inter-
mediate autophagy defect in Atg5 HET lines and a complete loss
of autophagy in KO lines. However, Atg5 KO ENL–MLL cell lines
showed substantial cell death, preventing meaningful interpreta-
tion of subsequent data. Together with the fact that heterozygous
loss of an autophagy gene is the most relevant genotype for AML,
we focused on the in vitro and in vivo analysis on the HET
genotype. However, the phenotypes of heterozygous VavAtg5+/−
and VavAtg7+/− mice were identical to WT and showed no clinical
symptoms even at 18 months of age (data not shown), suggesting
that a primary oncogenic event such as MLL–ENL fusion is
necessary to reveal this intermediate phenotype.
First we tested proliferation by examining MLL–ENL lines under
normal conditions and under tumor stress conditions: nutrient/
growth factor withdrawal and hypoxia. More colonies were
counted in control conditions and hypoxia in the HET MLL–ENL
line as compared with WT (Figure 3e). Analyzing short-term BrdU
incorporation versus DNA content (7AAD), the HET lines displayed
a proliferative advantage (S phase cells) following culture in
withdrawal conditions (Figure 3f with example of gating in G,
hypoxia and normoxia Supplementary Figure S4A and B). In
summary, a partial deficiency in autophagy leads to increased
proliferation in MLL–ENL leukemic lines in vitro. To assess the
impact of Atg5 loss on leukemia formation in vivo, primary Atg5
WT and HET MLL–ENL leukemic cells were injected into sublethally
irradiated hosts. At a time point at which 0/10 mice injected with
the Atg5 WT ENL–MLL lines had neither developed clinical
symptoms nor signs of leukemia, 10/10 mice injected with HET
Atg5 MLL–ENL lines had to be killed because of typical leukemic
clinical symptoms (Figure 3h). Representative FACS analysis
showed the evidence of development of a biphenotypic CD2+
CD11b+ and GFP+ leukemia (Figure 3).
Altered metabolism and growth pathways upon AML
development following heterozygous loss of Atg5
Cancer cells convert glucose into lactate via aerobic glycolysis
(termed the ‘Warburg effect’) to meet energetic demands and
support proliferation.34 To test whether increased proliferation
was accompanied by a shift toward glycolytic metabolism, we
analyzed the oxygen consumption rate (OCR) and lactate
production (extracellular acidification rate; ECAR) of the
MLL–ENL cell lines using the Seahorse analyzer. Although both
ENL–MLL lines displayed significant glycolysis, as previously
reported,35 the Atg5 HET cells displayed increased spare (unused)
respiratory capacity (OCR after FCCP treatment; Figures 4a and b)
and elevated basal ECAR (Figure 4c) compared with control lines.
This glycolytic phenotype was confirmed by increased enzymatic
quantification of lactate. Autophagy induction by Rapamycin
inhibited glycolysis in both genotypes, as expected, and restored
HET lactate production to levels comparable to the WT line
(Figure 4d). Increased staining for the main glucose transporter
Glut1 on the HET line confirmed increased glycolysis (Figure 4e).
Next, we asked whether the HET line relied more on glycolysis for
proliferation. Owing to ATP use for galactose processing,
conversion of galactose to pyruvate via glycolysis generates no
net ATP; therefore, cells must switch to oxidative phosphorylation
to meet energy needs.36 As expected, galactose cultured MLL–ENL
lines displayed minimal lactate generation (Figure 4f). Although
cell death was unaltered in galactose (not shown), the HET cells
showed a small but significant reduction in proliferation
(Figure 4g). This suggests that increased proliferation following
autophagy reduction in the HET is dependent on glycolytic
metabolism, indicating that the increased glycolysis might at least
partially cause the increased proliferation.
DISCUSSION
Autophagy genes, including Atg5, have been characterized as
haploinsufficient tumor suppressors lost in multiple tumor
types.12,37 Decreased levels of Atg5 have been associated with






(human genome, taken from
Ensembl Genome Browser)
Frequency chromosome lost
in complex karyotype AML; %
(n= 60, Rucker et al.26)
5q Chr 5: 79 741 823–159 483 514 Atg10 Chr 5: 81 267 844–81 572 241 77
Atg12 Chr 5: 115 163 897–115 177 555
7q Chr 7: 107 570 049–158 821 424 KLHDC10 Chr 7: 129 710 350–129 773 596 45
PRKAG2 Chr 7: 151 253 203–151 574 316
Atg9B Chr 7: 150 709 302–150 721 586
12p Chr 12: 100 000–32 700 000* GABARAPL1 Chr 12: 10 365 489–10 375 722 18
16q Chr 16: 59 672 953–88 827 254 GABARAPL2 Chr 16: 75 600 249–75 611 779 32
MAP1LC3B Chr 16: 87 425 406–87 438 385
17p Chr 17: 1–8 353 903 GABARAP Chr 17: 7 143 333–7 145 772 55
Correlation between the locations of autophagy pathway genes in the human genome, as compiled by Behrends et al.21 and chromosomal regions commonly
deleted in AML patients.22,24,56 P= 0.039 indicates the statistical probability of this number of core autophagy genes that are being deleted by chance,
assuming independent gene locations, Fisher’s exact test.
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reduced progression-free survival and increased proliferation in
melanoma.38 However, autophagy in AML biology has been
relatively uninvestigated. Our findings are compatible with
reduced expression levels of Atg8 homologs in AML blasts,
agreeing with a recent study across AML subtypes.39
We conclude that decreased autophagy could contribute, via
increased proliferation, to leukemic development. These results agree
with a recent study of Atg7 deletion in pancreatic cancer to suggest
deficient autophagy may augment tumor activity and metabolism.40
In that study and others, it appears that apoptotic impairment, for
example, via p53 deletion, may be vital to turn pro-proliferative
effects of Atg gene deletion into malignant benefits.40,41 As apoptosis
is affected by MLL–ENL,35,42 our results support this hypothesis.
However, previous findings were largely obtained in mouse cancer
models. Here, we found that the majority of human AML donors
measured retained low levels of autophagy activity and typically only
display heterozygous Atg deletions.
Enhanced proliferation and aerobic glycolysis are common
features of cancers, including AML.43 In addition to maintaining
healthy mitochondria, macroautophagy may control glycolysis via
the delivery of glycolytic enzymes to the lysosomes. Indeed,
chaperone-mediated autophagy was shown to degrade the M2
isoform of pyruvate kinase.44 A third mechanism would be the
degradation of free fatty acids (lipophagy) required to fuel the
mitochondrial β-oxidation.45 It is possible to envisage that
increased ROS may also have an impact on glycolysis.
In line with our data are the findings of a recent study showing
that deficiency in PINK1, a kinase that controls mitophagy, sustains
cell proliferation by re-programming glucose metabolism through
HIF1.46
Here we found that physiological autophagy levels ex vivo were
highest in immature hematopoietic HSPC populations. A similar
pattern was observed during differentiation of cultured human
stem cells.47 A recent study by Warr et al.18 highlighted the high
autophagy capacity of HSC and its importance in HSC stress
response; differences in the basal autophagy that Warr et al.
measured in multipotent cells could reflect the cytokine-replete
culture conditions used in many baseline controls for that study.
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Figure 2. Decreased autophagy in human AML blasts. (a) Expression of autophagy genes in blast marker-positive BMNCs from AML patients
relative to blast marker-negative cell expression (value for each donor represents the mean from three independent sorts, measured in
triplicate by Fluidigm, normalized to GAPDH). (b) Frequency of blast marker-positive or -negative cells from AML BMNCs with high LC3/LysoID
colocalization (BDS) under basal conditions or after E64D/Pepstatin A treatment (Basal+Inh; n= 13, Wilcoxon test comparing populations
within donors *Po0.05, **Po0.01, ***Po0.001). (c) Representative immunohistochemistry of p62 in bone marrow trephine samples from
AML patients (n= 8 donors) or healthy controls (n= 4 donors) either with antibody pre-incubated with blocking peptide or with antibody
alone (scale bar 50 μm). (d) The geometric mean fluorescence intensity of nonyl-acridine orange (NaO) and ROS (by MitoSOX) of blast marker-
positive BM cells from AML patients compared with CD34+ cells from healthy BM donors (Mann–Whitney test).
Autophagy prevents glycolysis and proliferation in AML
AS Watson et al
5

































































































































Figure 3. Heterozygous deletion of Atg5 in a MLL–ENL AML model mediates increased proliferation and leukemogenic potential.
(a) Generation of conditional Atg5−/− (KO), Atg5+/− (HET), Atg5+/+ (WT), empty vector or MLL–ENL transduced leukemic lines, in which
Cre-expressing retrovirus was used to delete Atg5 expression. (b) Western blot for Atg5 (Atg5 is typically only visible in Atg5/12 complex).
(c) LC3 or GAPDH protein levels in protein lysates from leukemic lines. (d) Geometric fluorescence mean intensity of CytoID staining of
MLL–ENL lines; Rapamycin treatment of WT lines serves as positive control. (e) difference in number of colonies formed in complete
methylcellulose by 500 cells from leukemic lines following 72-h culture in normoxia or 0.1% oxygen (n= 3 per line, representative of two
experiments). (f) Quantification of BrdU plots from leukemic lines under starvation, gated as in g, showing difference in frequency of cells in the S
phase or dead cells (sub-GO/G1; Cre-transduced subtract genotype empty vector frequency; n=5 cultures over three experiments) or (g)
representative plots of BrdU incorporation against DNA content (7AAD intensity) delineating cell cycle stages and dead cells (sub-GO/G1) in
leukemic lines starved for 18 h (reduced serum (2%) no growth factors). (h) Survival of sublethally irradiated C57BL/6 mice (2×3Gy) intravenously
injected with 1×106 primary leukemic cells with Atg5wt/wt or Atg fl/wt genotypes transduced with CRE-IRES-GFP retrovirus, sorted on GFP expression
pre-injection; 10 mice per genotype were scored regularly and killed on development of clinical symptoms with pre-determined score threshold. All
bar graph values are mean± S.E.M.; P-values are obtained with two-tailed t-test (*Po0.05), unless otherwise stated. See also Supplementary
Figure S4 for normoxia (Supplementary Figure S4A) and hypoxia (Supplementary Figure S4B).
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We predict that further investigation of the mechanistic
interplay between autophagy, energy metabolism and cell cycle
status in leukemic and stem cells will lead to a better mechanistic
understanding of stem cell fate decisions and the discovery of
new therapeutic strategies in anticancer therapy.
MATERIALS AND METHODS
Flow cytometry
Flow cytometry experiments were performed on LSRII (Becton Dickinson,
Oxford, UK) or CyAn (Beckman Coulter, High Wycombe, UK) instruments,
unless otherwise stated. Data were analyzed with FlowJo 8.8.6 for Mac
(Tree Star Inc., Ashland, OR, USA). Single-cell suspensions of human bone
marrow mononuclear cells (BMNCs) were rested overnight for 24 h in
IMDM 20% FCS before staining; single-cell suspensions of murine BM,
spleen and peripheral blood were stained immediately after harvesting. Fc
blocking and live/dead reagents were used for all appropriate experiments.
Absolute cell numbers in the peripheral blood were quantified using
TruCount tubes (Becton Dickinson). See Supplementary Tables 2–4 for
antibodies and reagents used.
CytoID assay
Autophagosomal content was quantified with the CytoID kit (Enzo Life
Sciences, Exeter, UK). Murine BM was cultured in CytoID dye (1 : 3000)
containing medium for 30min according to the manufacturer's protocol.










































































































































Figure 4. Heterozygous loss of Atg5 causes increased glycolytic dependence. (a) OCR with (b) quantification after addition of FCCP and (c)
basal ECAR of 280 000 cells from MLL–ENL cell lines assayed on the Seahorse Bioanalyzer with addition of mitochondrial inhibitors: (A)
Oligomycin 400 nM; (B) FCCP, 400 nM; (C) Rotenone 1 µM; (D) media only (mean± S.D., five cultures assessed per genotype, representative
experiment of two). (d) Enzymatic lactate assessment in supernatant of MLL–ENL lines after 48-h culture. (e) Histogram of Glut1 fluorescence
intensity of MLL–ENL cell lines. (f) Enzymatic assessment of MLL–ENL line lactate production during culture with 20mM glycolysis inhibitor
galactose (GAL) or 20mM glucose (GLU). (g) Frequency of cells in the S phase in Cre-transduced lines after culture with either 20 mM glucose
or galactose, first for 24 h in complete media (10% FCS and cytokines) then under starvation conditions for 18 h (2% serum, no cytokines;
n= 2, mean± S.E.M.). P-values were obtained with two-tailed t-test (*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001), unless otherwise stated.
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CD150+CD48−) and LSK (Lin−Sca1+cKit+) populations and were analyzed
using flow cytometry. Rapamycin and Wortmannin were used as internal
controls.
Imaging flow cytometry (image stream) and autophagy assay
After material preparation as above, where applicable samples were
suspended o1 × 106 cells/ml in either 1x HBSS 4.2 mM sodium
bicarbonate (starvation media, only where stated) or normal growth
media (IMDM 10% FCS for primary cells and as stated for cell lines) with
10 µg/ml E64D/Pepstatin A (Enzo Life Sciences), 1 µM Rapamycin (Sigma,
Gillingham Dorset, UK), 20 µM Chloroquine (Sigma) or 100 nM Wortmannin
(Sigma) for 2 h. Image stream measurement of autophagy was performed
as previously described,48 samples were acquired on the Image Stream 100
or Image Stream X (Amnis, Watford, UK), data obtained were analyzed with
the IDEAS 4.0.735 software (Amnis) for LC3/LysoID Bright Detail Similarity
(that is, the similarity between their fluorescent signals). Cells from LC3-
GFP transgenic mouse, previously published,49 were acquired on the IS100
and analyzed for spot count on a LC3 peak mask with a spot to cell
background ratio of 2.5 or 3.5. See Supplementary Tables 2–4 for
antibodies and reagents used.
Human BM
Healthy human BMNCs were obtained from Lonza (2M-125C, Verviers,
Belgium). AML and MDS BMNCs were obtained from MDSBio (experiments
approved by local REC, REC# 11/H0605/4 with informed consent).
RNA-seq
Human BM was sorted for HSC (Lineage−CD34+CD38−CD90+CD45RA), GMP
(Lineage−CD34+CD38+CD123+CD45RA+) and MEP (Lineage−CD34+CD38+
CD123−CD45RA−) populations; RNA was extracted and RNAseq analysis
was performed; reads per kilobase per million mapped reads for
autophagy genes was calculated using standard techniques.50
Fluidigm gene expression analysis
AML BMNCs were sorted on selected blast surface marker expression
(Supplementary Figure S6); 3 × 200 cells/population per donor. RNA was
extracted, selected autophagy and metabolic genes amplified and
analyzed for expression using a dynamic 48× 48 array (Biomark Fluidigm)
as previously described.51 See Supplementary Table 1 below for Taqman
gene expression assays.
P62 immunohistochemistry
Serial 4 µm sections of BM trephine samples taken from AML patients or
lymphoma patients with no BM involvement were stained with anti-
human p62 (Enzo Life Science BML-PW9860) using the Dako (Cambridge,
UK) EnVison+ Dual Link System (K4065) and standard techniques.
Synthetic peptide (HCPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYD-
IGAALDTIQYSKH-OH) pre-incubated with primary antibody at 400x molar
excess was used as negative control.
Mice
Vav Atg5/7−/− mice were on the C57BL/6 background, and bred and
housed in the Department of Biomedical Services, University of Oxford, in
individually ventilated cages. Age- and sex-matched mice were used at the
age of 6–9 weeks for all experiments, unless stated otherwise. VaviCre− ;
Atg5/7fl/fl and VaviCre+; Atg5/7fl/wt littermates were used equally as
controls. Vav-Atg7 breeding and genotyping are described previously.30
Atg5fl/fl mice were crossed to VaviCre mice to obtain VavAtg5. Atg5 wt and
flox genotyping were performed separately.52 All animal experiments were
approved by the local ethical review committee and were performed
under a UK home office license (PPL 39/2809).
Histology
BM was aseptically collected from 7-week-old VavAtg7−/− mice and
littermate controls, and stained using APC anti-mouse Gr1 and PE anti-
mouse CD11b and were then sorted using flow cytometry. Histology was
performed as previously described.30
BM cytospin
Filter cards were moistened with PBS before spinning. Overall, 5000 BM
cells from 6-week-old VavAtg5− /− mice or WT littermates were
resuspended in 200 µl of PBS/20% FCS and pipetted onto the filter cards
and then centrifuged with low acceleration, 1000 r.p.m. for 10min before
drying overnight. Slides were soaked in May–Grünwald for 5 min, washed
with DI water, before being transferred to Giemsa for 20min, and washed
with DI water again. Slides were then left to dry before mounting with
Pertex. Slides were inspected with an uninverted microscope and 100 cells
per slide were morphologically scored as: Neutrophil, Immature Myeloid,
Lymphocyte, Erythrocyte.
MLL–ENL line generation
BM from Atg5 fl/fl, Atg5 fl/wt and Atg5 wt/wt (Bl6) mice (three per
genotype) was extracted, crushed and pooled by genotype. Lineage cells
were depleted and Lin-negative cells transduced with constitutive
MLL–ENL, as previously described.32,33 The resulting lines were transduced
with pMSCV-IRES-CD2, containing the tailless human CD2 cDNA53 either
alone (empty vector) or with additional iCre54 and grown in RPMI, 10% FCS,
2 mM L-Glutamine, penicillin/streptomycin, 50 μM 2-mercaptoethanol,
100 ng/ml mSCF, 10 ng/ml mIL-3 and 10 ng/ml mIL-6.
Immunoblot
Protein was extracted using RIPA buffer with supplemental protease
Inhibitors (Roche, Welwyn Garden City, UK). Protein content was normal-
ized and samples boiled with 4x LDS sample buffer (Invitrogen,
Lutterworth, UK) and 20x Reducing agent (Invitrogen) and then run on a
4–12% Bis-Tris gel (Invitrogen). Proteins were transferred to PVDF
membranes (GE Healthcare, Little Chalfont, UK) and blocked overnight in
blocking buffer (TBS-T 5% skimmed milk). Primary antibodies (all Cell
Signaling (Hitchin, UK) except anti-Atg5 from Novus and anti-LC3 from
MBL-Int. (Woburn, MA, USA)) were incubated at 1 : 1000 in blocking buffer,
at 4 °C overnight. Secondary antibodies were Goat α-rabbit 800 CW or Goat
α-rat 680LT (Licor, Cambridge, UK). Blot detection was carried out using
Odyssey CLx Infrared Imaging System.
BrdU analysis
For multiday BrdU incorporation analysis, cell lines were cultured for 48 h
with 10 µM BrdU and then stained for incorporation as per the BrdU Flow
Kit (Becton Dickinson); cell cycle kinetics were analyzed following 40min
BrdU pulse. MLL–ENL line starvation was performed overnight with 2% FCS
and no cytokines; hypoxia treatment was 48 h in 0.1% oxygen.
Seahorse and metabolic assessments
In all, 2.8 × 105 cells per well were adhered to microplates using Cell Tak
(Becton Dickinson). Cells were washed and rested for 1 h in low-buffered
bicarbonate-free DMEM (pH 7.4) before rates of glycolysis and oxidative
phosphorylation were determined in 10 replicates for each genotype by
measuring lactic acid release (ECAR) and OCR using an XF24 XF analyser
(Seahorse Bioscience, Billerica, MA, USA) as previously described.55
Enzymatic lactate assessment used the Instruchemie kit (2864) in 96-
well plate.
Statistical analysis
Given prior experience with the VavAtg7 model, where we found 100%
penetrance for the vast majority of phenotypes, we usually chose the
number of WT and KO mice to be the minimum (n= 4) that still gives
statistical significance (Po0.05) using a Mann–Whitney test. The number
of mice in all other animal experiments (BM chimera, MLL-ENL in vivo
experiments) are shown or indicated. No animals or data were excluded.
Animals were never randomized. Blind analysis was performed by the
pathologist for the murine immunohistochemistry (Supplementary Figure S3E
and cell counts on blood smears (Supplementary Figure S3D). The exact
sample size (n), a description of the sample collection and the number of
times an experiment has been replicated is described in the appropriate
figure legends. Statistics analysis was performed using Graph Pad Prism 4,
error bars represent S.E.M. and P-values calculated with a two-tailed Mann–
Whitney test unless otherwise stated.
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ABBREVIATIONS
AML, acute myeloid leukemia; BM, bone marrow; GMP, granulocyte–
macrophage progenitors; ECAR, extracellular acidification rate; HET,
heterozygous; HSC, hematopoietic stem cells; HSPC, hematopoietic stem
and progenitor cells; KO, knock-out; LC3, microtubule-associated protein
light chain 3; LK, Lin − Sca1 − cKit+; LSK, Lin − Sca1+C-kit+; MDS, myelodys-
plastic syndrome; MLL–ENL, mixed lineage leukemia–eleven-nineteen
leukemia; OCR, oxygen consumption rate; ROS, reactive oxygen species;
WT, wild type.
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